Filing Flows › Keros Therapeutics (KROS) › Q1 2025
Keros Therapeutics (KROS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Keros Therapeutics (KROS) reported revenue of $211M for the first quarter 2025 (Q1 2025), up 2,544-fold from a year earlier and up 69-fold from the quarter before. Operating margin was 72.0%, net earnings $148M (70.3% of revenue).
Keros Therapeutics, Q1 2025: revenue $211M (2,544× year over year), operating margin 72.0%, net earnings $148M, operating cash flow $161M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $211M | 69× | 2,544× |
| Operating profit | $152M | — | — |
| Net earnings | $148M | — | — |
| Operating cash flow | $161M | — | — |
| Free cash flow | $161M | — | — |
What changed
Revenue was $211.2M in Q1 2025, up 254348% year over year and up 6843% from the previous quarter. License revenue was the largest line at 93% of revenue. Service and other revenue added $15.8M year over year (up 19046%), 7% of the total change.
Operating profit was $152.0M, a 72.0% margin (up 58485.2 points year over year). Total costs grew 22% against revenue growth of 254348%. The fastest-growing cost line was Research & development (+27%). Net earnings were $148.5M. The effective tax rate was 6.3%.
Operating cash flow was $161.2M, 109% of net earnings. Non-cash charges added back $344K of depreciation and $8.9M of share-based compensation. Capital expenditures of $565K left free cash flow of $160.6M.
Questions
What was Keros Therapeutics' revenue in the first quarter 2025?
Keros Therapeutics (KROS) reported revenue of $211M for the first quarter 2025 (Q1 2025), up 2,544-fold from a year earlier and up 69-fold from the quarter before.
Was Keros Therapeutics profitable in the first quarter 2025?
Operating profit was $152M (72.0% of revenue) and net earnings $148M.
Source: Keros Therapeutics 10-Q on SEC EDGAR.